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Abstract In the diagnostic work-up of hereditary
non-polyposis colorectal cancer (HNPCC, Lynch syn-
drome), high-risk patients can be identiﬁed using
information from the family history on cancer
(‘Amsterdam criteria’ and ‘Bethesda guidelines’). To
investigate to what extent the medical specialists apply
these criteria to patients with colorectal carcinoma and
a suspicion of HNPCC, we collected information on
diagnostic work-up of 224 patients of seven hospitals in
the region of the Comprehensive Cancer Centre West
in Leiden, The Netherlands. These patients were
diagnosed with colorectal cancer between 1999 and
2001 and satisﬁed at least one of the Bethesda guide-
lines. A complete family history was recorded for 38 of
the 244 patients (16%). Patients with a complete family
history were more likely to be referred to the Clinical
Genetic Centre than those with an incomplete or ab-
sent family history (53% vs. 13% and 4%, respectively;
P < 0.0001), and more likely to be analyzed for
microsatellite instability (MSI), which is a characteris-
tic of HNPCC (34% vs. 6% and 1%, respectively;
P<0.0001). We conclude that the family history is
neglected in the majority of patients with colorectal
cancer and MSI-analysis is only performed in a small
proportion of the patients that meet the guidelines for
this analysis.
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Introduction
Colorectal cancer (CRC) is one of the most common
forms of cancer in Western society. Every year 9,500
patients in the Netherlands are diagnosed with the
disease and almost half of them die from it (Dutch
Cancer Registry, 2002). It is estimated that in around
20% of the patients with a colorectal tumour genetic
factors play a role in the aetiology [1]. About 1–5% of
the patients with CRC are thought to have hereditary
non-polyposis colorectal cancer (HNPCC, Lynch
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caused by a defect in one of the DNA-Mismatch Re-
pair (MMR) genes [2]. The most important clinical
characteristics of CRC associated with HNPCC, are
the relatively young age at which patients are diag-
nosed with the disease (average <45 years old) and the
proximal localisation of the tumour in the colon. Be-
sides an increased risk of developing a tumour in the
colon, there is an increased risk of developing a tumour
elsewhere in the body, especially in the endometrium
(lifetime risk: 50%), the small intestines, the ovaries,
the brain, the urinary tract, the biliary tract and the
development of a keratoacanthoma or a carcinoma of
the sebaceous glands of the skin [3].
The identiﬁcation of patients with hereditary colo-
rectal carcinoma is of great importance for the patient,
because the treatment and follow-up of the tumour
differ from those with non-hereditary colorectal carci-
noma [4]. Furthermore, the identiﬁcation of these
patients is important, because it offers efﬁcient
manners for the prevention of colorectal carcinoma
and other forms of cancer for the patient himself
as well as his family [5]. It has been shown that a
colonoscopy every three years can lead to a decline in
mortality of at least 65% [6].
The genetic defect in HNPCC can be detected by
immunohistochemic staining of the MMR proteins in
tumour cells [7]. Another method to select families for
mutation analysis of the MMR genes is analysis of
errorsinrepetitiveDNA-sequences,i.e.,MicroSatellite
Instability (MSI) [8]. MSI is found in around 15% of the
non-selected CRC and in more than 95% of the colo-
rectal tumours associated with HNPCC [9]. In 1996,
guidelines were formulated for patients whose tumours
should be analyzed for MSI [10]. These so-called
Bethesda-guidelines describe practically all situations,
where there is a suspicion of HNPCC. Recently these
guidelines have been revised (Table 1)[ 11].
Before the discovery of the MMR-genes, the most
common approach in the diagnostic work-up for
HNPCC was to use the ‘Amsterdam criteria’. These
criteria are met if there are, within one family, three
individuals with a colorectal (or another HNPCC-
associated kind of) tumour, of whom one person is a
ﬁrst degree family member of the other two and at
least one carcinoma is diagnosed before the age of ﬁfty
[12]. To evaluate the Amsterdam criteria in patients
with CRC, a complete history on cancer in the patient’s
family has to be obtained. Until now it is not known
whether an adequate family history is taken of all
patients with a colorectal carcinoma. We also do not
know to what extent medical specialists use the above
mentioned clinical Bethesda guidelines and if the
tumours of all the patients who match the criteria are
tested for MSI. The objective of the present study was
to answer these questions using data of the Cancer
Registry of the Comprehensive Cancer Centre West
(CCCW) in Leiden, The Netherlands.
Patients and methods
We selected patients who were diagnosed with a pri-
mary and invasive colorectal tumour in the period
1999–2001 from the Cancer Registry (CR) of the
Comprehensive Cancer Centre West (CCCW) in The
Netherlands. The patients had to satisfy one of
the following two Bethesda guidelines: the patient had
to have more than one tumour, i.e., one colorectal
carcinoma and a second one (colorectal cancer or
another HNPCC-associated kind of tumour), or the
patient had to be ﬁfty years or younger at diagnosis.
The selected patients were considered to have an
indication for the performance of MSI-analysis and/or
referral to the Clinical Genetic Centre (CGC). Patients
with a carcinoma in situ or a carcinoı ¨d of the appendix
were not included in the analysis.
Between 1999 and 2001, 434 patients who complied
with the above mentioned criteria were diagnosed with
CRC in one of the twelve hospitals in the CCCW-
region. Seven hospitals gave permission for the
collection of information concerning family history,
MSI-analysis and referral to the CGC. We extracted
this information from the various (electronic) medical
reports. The family history was considered complete if
the medical records reported on cancer in the family,
and if so, information about the age at the time of the
Table 1 Guidelines for the performance of MSI-analysis of
colorectal tumour [11]
Revised Bethesda-guidelines
A person with colorectal carcinoma diagnosed at age £50
A person with colorectal carcinoma and MSI-associated
pathology
a <60 years
A person with colorectal carcinoma and a HNPCC
associated tumour
b
A person with colorectal carcinoma and a ﬁrst degree relative
with a colorectal or HNPCC associated tumour; at least one
of the tumours is diagnosed before the age of 50
Three relatives diagnosed with colorectal carcinoma or
a HNPCC associated tumour, diagnosed at any age; one
patient needs to be a ﬁrst degree relative of the other two
a The presence of tumor-inﬁltrating lymphocytes, so called,
‘‘Crohn’s like lymfocyte reaction’’, mucinous or signet ring cell
carcinoma differentiation or medullary growth pattern
b Carcinoma of the endometrial tissue, stomach, small intes-
tines, pancreatic gland, biliary tract, urinary tract, ovaries,
brain, keratoacanthoma and carcinoma of the sebaceous glands
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cancer within ﬁrst-degree and second-degree family
members.
Data were collected of 244 patients. Of these
patients, 120 patients had multiple tumours, 109
patients were ﬁfty years or younger at the time of
diagnosis, and 15 patients had both characteristics. For
comparisons between patients with multiple tumours
and patients who were young at diagnosis, those with
both characteristics were allocated to the ‘‘multiple
tumours’’ group. The data were analyzed using
SPSS statistical software (version 12.0.1). Univariate
comparisons of proportions between patient groups
were performed by Chi-squared test. Multivariate
logistic regression analysis was used to study whether
the presence of a complete family history or referral to
a CGC could be explained by age, sex, inclusion
criterion (multiple tumours or young age at diagnosis),
hospital or type of medical specialist.
Results
The study group consisted of 244 persons, who com-
plied with one of the Bethesda guidelines and there-
fore were considered to be referred for MSI-analysis
and/or genetic counselling. The male:female ratio was
49:51 and did not differ between the groups selected on
the basis of multiple tumours or age £50 years at
diagnosis.
A complete family history was recorded in the
medical records of 38 (16%) of the 244 patients. For
136 patients (55%) limited information on the family
history was available, and for 70 (29%) patients no
information on the family history was found in the
medical records. In the seven participating hospitals, a
family history was reported for 38–91% of the patients.
Of the 38 patients with a complete family history, 20
(53%) were referred to the CGC. This percentage was
higher than that of patients with an incomplete family
history (13%) and that of patients without any infor-
mation on family history (4%) (P < 0.0001, Table 2).
MSI-analysis was performed more often in the patients
with a complete family history: 34% of patients with a
completefamilyhistorycomparedto6%ofpatientswith
anincompletefamilyhistoryand1%ofpatientswithout
any family history (P<0.0001) (Table 2). Presence of a
complete family history and the performance of
MSI-analysiswerenotassociatedwithage,sex,inclusion
criterion (multiple tumours or young age at diagnosis),
hospital or type of medical specialist (multivariate
logistic regression analysis; data not shown).
Discussion
We used the Bethesda-guidelines to select a group of
patients with a suspicion of HNPCC. These patients
were diagnosed with colorectal cancer between 1999
and 2001, a period during which MSI-analysis and the
Bethesda guidelines were already available. Therefore
we expected that for these patients, physicians would
have examined and reported their patients’ family
history and that MSI-analysis would have been per-
formed. In our study group, however, the family his-
tory of the patients diagnosed with colorectal
carcinoma was not sufﬁciently examined and reported
in the medical records. For this reason, we believe the
Bethesda-guidelines were not sufﬁciently applied by
the physicians. As a consequence, MSI-analysis was
performed on a small proportion of the tumours. More
patients with a complete family history in their medical
records were referred by their physicians to the CGC
than patients without such a family history. MSI-anal-
ysis was also performed more often in this group. We
expect that in a low-risk population, i.e., patients with
colorectal cancer who do not meet the Bethesda
guidelines, these results would be even more dramatic.
On the one hand, our results may appear to be
better than they actually are. We collected our data
using medical records from various medical specialties,
while the treating physician will not have this overview
in practice. On the other hand, it is possible that when
a physician examined a family history and none of the
family members was diagnosed with cancer, he did not
report it in the medical records. In this case, the family
history was considered as absent, although it in fact was
examined. Nevertheless we expect that if MSI-analysis
was performed or the patient was referred to the CGC,
this would have certainly been reported.
Table 2 Diagnostic work-up
for HNPCC in 244 patients
with colorectal cancer, by
completeness of the family
history as reported in the
medical records
Diagnostic workup Family history
complete (n = 38)
Family history
incomplete (n = 136)
Family history
absent (n = 70)
Referred to CGC 20 (53%) 17 (13%) 3 (4%)
MSI-analysis performed 13 (34%) 8 (6%) 1 (1%)
Results of MSI-analysis 3 MSI, 10 stable 7 stable, 1 unknown 1 stable
Diagnosis of HNPCC 6 (16%) 3 (2%) 1 (1%)
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diagnostic workup for CRC differed widely. For the
seven participating hospitals, the proportion of patients
with a reported family history on cancer ranged from
38% to 91%. Furthermore, only half of the approached
hospitals were willing to cooperate. For these reasons,
we cannot generalise our results for the whole CCCW-
region. Nevertheless, we conclude that the family his-
tory appears to be neglected in the majority of patients
with colorectal cancer in our study period, and that
MSI-analysis was only performed in a small proportion
of the patients that meet the guidelines for this analy-
sis. Possibly, the attention for identiﬁcation of patients
with HNPCC has increased in more recent years. Our
ﬁndings underscore the importance of implementation
of family history and Bethesda guidelines in the
physician education.
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